Last reviewed · How we verify
Rectal Diclofenac
At a glance
| Generic name | Rectal Diclofenac |
|---|---|
| Sponsor | Assumpta Nnenna Nweke |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparative Clinical Study to Evaluate the Possible Efficacy and Safety of Oral N-Acetyl Cysteine Versus Rectal Diclofenac in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis (PHASE1, PHASE2)
- Intramuscular Versus Rectal Diclofenac for Pain Relief After Cesarean Section in Women (PHASE4)
- Indian National Study to Assess Incidence and Severity of Post-ERCP Pancreatitis After Following SOP
- Precise Endoscopic Application of Nitroglycerin in Preventing Post-ERCP Pancreatitis (PHASE4)
- Rectal NSAIDs With/Without PD Stent for PEP Prevention (NA)
- Indomethacin vs Diclofenac for Preventing PEP (NA)
- Rectal Versus Intramuscular Diclofenac for Pain Relief Following Caesarean Section (NA)
- Prevention of Post-ERCP Pancreatitis by Indomethacin Vs Diclofenac (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rectal Diclofenac CI brief — competitive landscape report
- Rectal Diclofenac updates RSS · CI watch RSS
- Assumpta Nnenna Nweke portfolio CI